Hims & Hers Health Inc. HIMS shares are climbing after Barclays reiterated its bullish stance and lifted its price target ...

Shares of Hims & Hers Health (NYSE:HIMS) are under pressure after JPMorgan trimmed its price target on the consumer telehealth name following a messy first quarter. The firm lowered its price target ...

Shares of Hims & Hers Health (HIMS) slipped 2% in overnight trading late Sunday after the company's chief medical officer ...

Hims & Hers Health (NYSE:HIMS) absorbed another analyst downgrade. Bank of America cut its price objective on Hims & Hers stock to $30 from $32, while keeping a Neutral rating. The firm called the ...

・HIMS to offer treatment options for perimenopause and menopause via its platform ・Rising U.S. demand for hormone therapy strains supplies of estrogen patches. ・BofA raises HIMS price target but ...

The average one-year price target for Hims & Hers Health (NYSE:HIMS) has been revised to $30.00 / share. This is a decrease of 30.94% from the prior estimate of $43.45 dated February 1, 2026. The ...

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 10 Fastest Growing NYSE Stocks to Buy. On February 24, 2026, Barclays lowered its price target on Hims & Hers Health, Inc. (NYSE:HIMS) to $25 from $48 ...

Hims & Hers Health, Inc. (NYSE:HIMS) ranks among the most shorted stocks to buy according to analysts. Following Novo Nordisk’s lawsuit against Hims & Hers Health, Inc. (NYSE:HIMS), Canaccord Genuity ...

Last Thursday, Hims & Hers Health announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Novo Nordisk’s ...